Borvák J, Kasanická J, Mayer V
Institute of Virology, Slovak Academy of Sciences, Bratislava.
Acta Virol. 1992 Oct;36(5):428-34.
3'-azido-2', 3'-deoxythymidine (AZT) concentrations in spiked human plasma were determined by means of reversed-phase high performance liquid chromatography (RP-HPLC). Samples were first cleaned-up for analysis using solid-phase extraction (SPE) columns filled with Silipore C18. In the concentration range comprising usual peak plasma concentrations during AZT therapy (0.1-20 mumol/l, i.e. 0.026-5.34 micrograms/ml) mean efficiency of the extraction procedure reached as high as 75.3% of original AZT concentrations in standard unextracted aqueous solutions. Replicate analyses in this range gave satisfactory intra-assay precision and reproducibility with coefficient of variation less than 11.3%. Calibration curves both in water and plasma showed good linearity (r > 0.999). The detection limit in plasma was 2 mumol/l, i.e. 5.3 ng per a 20 microliter of sample injected to the HPLC column. Plasma levels of AZT after a single dose administration, determined by HPLC and RIA showed rather poor correlation (r = 0.8900). In RIA about 1.7-4.5 times higher concentration values were obtained in a relatively short time, and, consequently, this method may better fulfil the needs of routine drug monitoring.
采用反相高效液相色谱法（RP-HPLC）测定加标人血浆中3'-叠氮-2'，3'-脱氧胸苷（AZT）的浓度。首先使用填充有Silipore C18的固相萃取（SPE）柱对样品进行净化处理以用于分析。在包括AZT治疗期间常见的血浆峰值浓度的浓度范围内（0.1 - 20 μmol/l，即0.026 - 5.34 μg/ml），萃取程序的平均效率高达标准未萃取水溶液中原始AZT浓度的75.3%。在此范围内进行的重复分析给出了令人满意的批内精密度和重现性，变异系数小于11.3%。水和血浆中的校准曲线均显示出良好的线性（r > 0.999）。血浆中的检测限为2 μmol/l，即每20微升注入HPLC柱的样品中为5.3纳克。通过HPLC和放射免疫分析（RIA）测定单剂量给药后血浆中AZT的水平，结果显示相关性较差（r = 0.8900）。在RIA中，在相对较短的时间内获得的浓度值高出约1.7 - 4.5倍，因此，该方法可能更能满足常规药物监测的需求。
